New insights into missed endpoint trial.
D065100:CCR5 Receptor Antagonists; D002986:Clinical Trials as Topic / Q000592:standards*; D003510:Cyclohexanes / Q000627:therapeutic use*; D023381:Endpoint Determination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000378:metabolism / Q000472:pathogenicity; D006801:Humans; D000077592:Maraviroc; D018579:Patient Selection; D019718:Receptors, CXCR4 / Q000378:metabolism; D014230:Triazoles / Q000627:therapeutic use*
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D019718:Receptors, CXCR4; D014230:Triazoles; D000077592:Maraviroc